Late Breaking News Articles
Clear filter
Late-Breaking HOPA News: NeoADAURA: Advancing Neoadjuvant Osimertinib for Resectable EGFR-Mutated NSCLC
Wai Tak Vince Sung, PharmD, MBA, BCOP, BCSCP, breaks down the results from the NeoADAURA trial and what its findings may mean for neoadjuvant osimertinib's role in the treatment of resectable EGFR-mutated NSCLC.
Late-Breaking HOPA News: Belantamab Mafodotin-bmlf Returns: FDA Restores BCMA-Targeted ADC Option for RRMM
Marshall Winget, PharmD, and Bradley Yelvington, PharmD, BCOP, discuss the recent reapproval of belantamab mafodotin in BCMA-directed therapy for relapsed or refractory multiple myeloma.
Late-Breaking HOPA News: The Evolving Landscape of NPM1-Mutated AML
Moh'd Mohanad A. Al-Dabet, PhD, AHI(AMT); Katia Al-Sawalha, BSc; and Olivia White, PharmD, BCOP, review revumenib and ziftomenib for NPM-1m disease and highlight key considerations when implementing these two therapies.
Late-Breaking HOPA News: Lurbinectedin and Atezolizumab for Extensive-Stage Small Cell Lung Cancer
Ming-Hei Tai, PharmD, BCOP, and Alexis Chapman, PharmD, BCOP, discuss the IMforte trial concerning lurbinectedin and atezolizumab in the treatment of extensive-stage small cell lung cancer.
Late-Breaking HOPA News: The Emerging Use of Bispecific Antibodies with Chemotherapy in Diffuse Large B-Cell Lymphoma
Katelynn Granger, PharmD, BCOP, and Matthew Warrick, PharmD, BCPS, BCOP, dive into the emerging use of bispecific antibodies with chemotherapy in diffuse large B-cell lymphoma.
Late-Breaking HOPA News: Fam-trastuzumab deruxtecan-nxki for HER2 Ultralow Metastatic Breast Cancer
The ability of fam-trastuzumab deruxtecan-nxki to treat breast cancer patients with HER2 IHC 0 with positive membrane staining up to IHC 3+ has changed the treatment paradigm for metastatic disease.
